Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time to review the results from the pivotal Phase 3 AMPLIFY study of tenapanor in combination with phosphate binders in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not controlled with binders. Tenapanor is Ardelyx’s investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor.
To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 9789472. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company’s website at www.ardelyx.com. The webcast will be archived and available for replay for 60 days following the call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.